Figure 9.
Effect of Lapatinib on the phosphorylation of CTFs and on tumour growth. (A) Cells stably transfected with cDNAs encoding HER2 ΔNar I were treated with lapatinib (10 μM) during 8 h. Cell lysates were immunoprecipitated with anti-HA antibodies and analyzed by Western blot with the same antibody or anti-phosphotyrosine antibodies as indicated. Note that the T47D clone used in (A) express higher levels of CTFs than that used in Figure 8B. (B) The same cells T47D cells expressing CTFs used in Figure 8A and B were subcutaneously injected into nude mice. Tumor volumes were measured at the indicated days after injection. Lapatinib was given orally from day 22th (arrow) twice a day at a dose of 75 mg/kg. The vehicle was administered to the control group.